The study supports prior research that found the same thing.

Ozempic is not marketed as a weight loss drug and is prescribed to those with type 2 diabetes to help manage their condition ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

1:54 GLP-1 drugs like Ozempic, Wegovy reduce Alzheimer’s risk for those with diabetes Two major studies published Monday in JAMA Neurology found that GLP-1 medications are linked to a lower risk ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

Medications designed to treat diabetes by lowering blood sugar levels, like Ozempic, continue to turn up added benefits, and ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

Semaglutide — the powerful ingredient behind Wegovy and Ozempic — has long been hailed ... seems to be promising in reducing the risk of Alzheimer's disease and related dementias (ADRD)'.

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.